Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

GALANTAMINE HYDROBROMIDE

All products: not a benefit

Other products in the same Health Canada class (N06DA) — coverage varies; not interchangeable

  • Donepezil (Aricept RDT): limited Use 347, 348, Not a benefit
  • Rivastigmine (Exelon): limited Use 347, 348, Not a benefit

Reminyl ER · DIN 02266717 · 8mg · extended release capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-04-03 — choose a marketed DIN from the same-category list.Discontinued 2017-04-03 · checked 2026-09-20
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-04-03 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-04-03 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347 Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed. Network note: Maximum duration 3 months. Coverage limit: LU Authorization Period: 1 year Reason for Use code 348 Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Reminyl ER · DIN 02266717 Manufacturer: Janssen Inc.; listing date 2006-01-12 Health Canada: Cancelled post market since 2017-04-03 · brand REMINYL ER · ATC N06DA04 GALANTAMINE · form Capsule (extended-release) · route Oral · ingredients GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Reminyl ER: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75213 · Verify on the e-Formulary ↗ (DIN 02266717)

Source record
DIN 02266717: Reminyl ER Raw flags: notABenefit=Y, sec3=Y Item: 120400031; group id 194; item number 0356; lccId 00027; manufacturer id JAN Source form: ER Cap; strength: 8mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02266717 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75213
Interchangeable products
Auro-Galantamine ER · DIN 02425157 · $1.2465 Galantamine ER · DIN 02443015 · $1.2465 Galantamine ER · DIN 02562154 · $1.2465 Mylan-Galantamine ER · DIN 02339439 · $1.2465 Pat-Galantamine ER · DIN 02316943 · $1.2465
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2017-04-03 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (12:04 Parasympathomimetic (Cholinergic) Agents) and how they are covered

Matched class: 12:04 Parasympathomimetic (Cholinergic) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETHANECHOL CHLORIDE, CARBACHOL, PYRIDOSTIGMINE BROMIDE 12:04 Parasympathomimetic (Cholinergic) Agents

DONEPEZIL HCL

· 48 products · Off-Formulary Interchangeable, not an ODB benefit (6), Limited Use, codes 347, 348 (42) · strengths: 5mg, 10mg · Orally Disintegrating Tab, Tab

RIVASTIGMINE

· 34 products · Limited Use, codes 347, 348 (28), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 1.5mg, 3mg, 4.5mg, 6mg, 9mg/5 Sq Cm, 18mg/10 Sq Cm · Cap, Trans Patch

BETHANECHOL CHLORIDE

· 3 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CARBACHOL

· 1 products · General benefit · strengths: 2mg · Tab

PYRIDOSTIGMINE BROMIDE

· 4 products · General benefit · strengths: 180mg, 60mg · LA Tab, Tab

PILOCARPINE HCL

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:04
Full class listing Related classes: 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:12 Sympathomimetic (Adrenergic) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: dementia of the alzheimers type
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. DONEPEZIL HCL · Off-Formulary Interchangeable, not an ODB benefit (6), Limited Use, codes 347, 348 (42) 1 INDICATIONS ARICEPT (donepezil hydrochloride) is indicated for: • symptomatic treatment of patients with mild, moderate and severe dementia of the Alzheimer’s type. PM: https://pdf.hres.ca/dpd_pm/00077966.PDF; date AUG 12, 1997; DIN 02232043; fetched 2026-09-10 Product monograph RIVASTIGMINE · Limited Use, codes 347, 348 (28), Off-Formulary Interchangeable, not an ODB benefit (6) 1 INDICATIONS EXELON® (rivastigmine hydrogen tartrate) is indicated for: • The symptomatic treatment of patients with mild to moderate dementia of the Alzheimer's type. PM: https://pdf.hres.ca/dpd_pm/00085220.PDF; date 2026-07-02; DIN 02242115; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications Galantamine ER (galantamine extended release capsules) is indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer’s type. Galantamine has not been studied in controlled clinical trials for longer than 6 months. Galantamine ER should only be prescribed by (or following consultation with) clinicians who are experienced in the diagnosis and management of Alzheimer’s disease. 1.1. Pediatrics Pediatrics (<18 years of age): No data are available in children. Therefore, the use of Galantamine ER is not recommended in children under 18 years of age. 1.2. Geriatrics Geriatrics (≥85 years of age): There is limited safety information for galantamine in this patient population (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00085752.PDF PM date: 2026-08-11 Source product: GALANTAMINE ER; DIN 02316943; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Reminyl ER: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026